10-Q: Zeo ScientifiX Q3 Loss Widens Amid Going Concern Doubt

Zeo ScientifiX reported a significantly wider net loss and expressed substantial doubt about its ability to continue as a going concern, despite revenue growth from its PPX service platform.

Summary

• Net loss for the three months ended July 31, 2025, widened to $2,072,000 from $1,012,000 in the prior year period.
• Net loss for the nine months ended July 31, 2025, increased to $4,706,000 from $3,451,000 in the prior year period.
• Revenues for the three months ended July 31, 2025, increased by 19.7% to $1,306,000, primarily due to growth in the PPX service platform.
• Revenues for the nine months ended July 31, 2025, increased by 5.0% to $3,545,000, also driven by the PPX service platform.
• General and administrative expenses surged by 51.0% to $3,149,000 for the three months and by 14.1% to $7,588,000 for the nine months, largely due to increased stock-based compensation.
• Cash balance decreased to $314,000 as of July 31, 2025, from $657,000 at October 31, 2024.
• The company continues to operate with a stockholders deficit, which worsened to $2,314,000 at July 31, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• Disclosure controls and procedures were deemed not effective as of July 31, 2025.

Sentiment

Score: 2

Explanation: The company reported a substantially wider net loss, a declining cash position, and an increasing stockholders deficit. Management explicitly raised substantial doubt about its ability to continue as a going concern. While revenues increased, this was overshadowed by a disproportionate surge in general and administrative expenses, largely due to stock-based compensation, indicating poor cost control relative to revenue growth. The termination of a key sales agreement and ongoing legal proceedings further compound the operational and governance risks, compounded by ineffective disclosure controls.

Positives

• Revenues increased by 19.7% for the three months ended July 31, 2025, to $1,306,000, and by 5.0% for the nine months to $3,545,000.
• The PPX service platform showed significant revenue growth, increasing its contribution to overall revenues from 14.4% to 27.8% for the three-month period and from 9.7% to 24.8% for the nine-month period.
• Cash used in operating activities decreased significantly to $335,000 for the nine months ended July 31, 2025, from $1,084,000 in the prior year, indicating improved operational cash burn.
• Secured a subscription agreement for $1,000,000 through the sale of 250,000 common shares, with initial installments received.
• Acquired BioLumina assets, including finished goods inventory and intellectual property, for $200,000, expanding product offerings.
• Entered into a Binding Memorandum of Understanding for a joint venture with BioXtek, LLC, aiming for operational efficiencies and new product development in wound care and surgical markets.

Negatives

• Net loss significantly widened to $2,072,000 for the three months ended July 31, 2025, from $1,012,000 in the prior year.
• Net loss for the nine months ended July 31, 2025, increased to $4,706,000 from $3,451,000 in the prior year.
• General and administrative expenses increased substantially by 51.0% for the three months and 14.1% for the nine months, primarily due to higher stock-based compensation.
• Cash balance declined to $314,000 as of July 31, 2025, from $657,000 at October 31, 2024.
• The company reported a growing stockholders deficit of $2,314,000 at July 31, 2025.
• Revenue from higher concentration allogenic aesthetic biologics decreased by 15.9% for the nine-month period, indicating market competition.
• Other income decreased significantly due to a reduction in non-recurring gains from prior periods.
• Disclosure controls and procedures were deemed not effective as of July 31, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months due to recurring net losses, negative cash flows from operations, and a stockholders deficit.
• Uncertainty regarding FDA regulations (Section 351 of the Public Health Services Act) for HCT/Ps, which may restrict the sale of current products without an approved biologics license application (BLA).
• Dependence on additional investment capital to fund ongoing operating expenses and research and development costs, with future funding likely to be costly and dilutive.
• Inability to pledge assets for additional borrowing, limiting financing options.
• Reliance on the ability to produce and sell products subject to changing technology and regulations.
• Current market capitalization, common stock liquidity, and available authorized shares may hinder the ability to raise equity proceeds.
• Risk of legal proceedings, including a lawsuit from a former Chief Science Officer for $150,000 severance and a dispute with Exotropin LLC over a terminated sales agreement and co-developed product.
• Failure to achieve a stabilized source of revenues since July 2015.
• Potential adverse impact on growth objectives without sufficient cash reserves.
• Risk that research and development activities will not be successful or that the company will be able to timely fund the required costs of those activities.
• Material weaknesses in internal control over financial reporting.

Future Outlook

Management anticipates continued dependence on additional investment capital to fund ongoing operating expenses and research and development costs for new products and clinical studies. The company is pursuing efforts to complete approved clinical studies and obtain approval for additional studies for specific indications. Efforts are underway to mitigate potential risks from adverse FDA rulings, including expanding international sales and developing new product offerings not subject to current regulations. The company is also working towards establishing a joint venture with BioXtek, LLC to develop and commercialize membrane patches and obtain an FDA BLA license for these products.

Management Comments

• Management cautions all readers that the forward-looking statements contained in this Report are not guarantees of future performance, and management cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will in fact occur.
• We do not believe that our products fall within these guidelines [FDA HCT/Ps regulations] and intend to vigorously defend against any adverse interpretation by the FDA on the classification of our products that may be deemed as falling under this defined regulation, if any.
• Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products.
• The Company's current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all.
• As of July 31, 2025, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.
• Our Interim Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act were recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that our disclosure controls are not effectively designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Industry Context

The biopharmaceutical industry, particularly in regenerative medicine, is highly regulated, with significant challenges in navigating FDA approval processes for novel therapies like HCT/Ps. Zeo ScientifiX's focus on perinatal-derived products and autologous biologics places it in a competitive and evolving segment. The shift in revenue mix towards the PPX service platform and away from allogenic aesthetic biologics suggests market dynamics favoring personalized or service-based treatments, or increased competition in the aesthetic biologic space. The pursuit of a joint venture for wound care and surgical markets indicates a strategic diversification within the broader healthcare sector, aiming for FDA BLA licenses which are critical for commercialization in traditional biologics.

Management Changes

Corporate Governance

Legal Proceedings

• Howard Golub, M.D., former Chief Science Officer, filed a complaint on November 19, 2024, alleging breach of contract for $150,000 severance, plus interest and attorney fees. The company intends to vigorously defend.
• The company provided formal notice of termination of a Sales Representative Agreement with Exotropin LLC for cause on August 15, 2025. Exotropin denied allegations and responded with demands, including cessation of sales of the co-developed product. The company is evaluating legal options.

Related Party Transactions

• Sales of approximately $37,000 (Q3 2025) and $61,000 (9 months 2025) of product to a management services organization (MSO) in which Dr. George Shapiro, the Company's Chief Medical Officer and a board member, has an indirect economic interest.
• Investment of $145,000 in non-marketable equity securities of Exotropin, an affiliate.
• Received a capital call notice from Exotropin in November 2024 for $126,000; company has not committed to participating, which would reduce its interest from 9.0% to approximately 5.6%.
• Awarded warrants to purchase 55,000 shares of common stock to Greyt Ventures, LLC, a principal shareholder, for consulting services on May 8, 2025.

Stakeholder Impact

• Shareholders: Significant dilution risk from future capital raises, convertible debt, and stock-based compensation. Increased net losses and going concern doubt pose a substantial risk to investment value. Ineffective disclosure controls may impact transparency.
• Employees: Changes in management (Dr. Everts' resignation, Mr. Borsheim's appointment) and potential restructuring due to going concern issues could affect job security and morale. Stock-based compensation is a significant part of G&A.
• Customers: Potential impact on product availability or service continuity if FDA regulations restrict sales or if the company faces severe financial distress. Disputes with partners like Exotropin could affect product offerings.
• Creditors: Going concern doubt and increasing liabilities (accounts payable, finance lease obligations) raise concerns about the company's ability to meet its financial obligations. Convertible promissory notes add complexity.
• Suppliers: Increased accounts payable and accrued expenses could indicate potential payment delays or strain on supplier relationships.

Next Steps

• Complete approved clinical studies and obtain approval for additional studies for other specific indications.
• Continue efforts to mitigate potential risks associated with adverse FDA rulings on HCT/Ps, including expanding international sales and developing new product offerings.
• Work in good faith towards the preparation, authorization, execution, and delivery of definitive agreements for the joint venture with BioXtek, LLC.
• Secure funding for the SPE Business within the BioXtek joint venture.
• Relocate current operations to the BioXtek Facility in Pompano Beach, Florida, expected by May 31, 2025.
• Vigorously defend against the lawsuit filed by former Chief Science Officer Howard Golub.
• Evaluate legal options and protect rights regarding the terminated Sales Agreement and Collaboration with Exotropin.
• Amortize approximately $554,000 of unamortized compensation associated with unvested stock grants over their remaining service periods.
• Amortize approximately $670,000 of unamortized compensation associated with options over their remaining service periods.
• Amortize approximately $1,678,000 of unamortized compensation associated with warrants over their remaining service periods.
• Make minimum of 8 purchase orders under the exclusive supply agreement with a third-party contract manufacturer for CDMO Products.
• Pay an additional $225,000 deposit to the CDMO upon confirmation of cGMP processing initiation.
• Continue receiving monthly installments for the $1,000,000 stock subscription until May 1, 2026.

Key Dates

Recommendation

The filing presents a highly concerning financial picture. The company reported significantly wider net losses, a declining cash balance, and a worsening stockholders deficit. Management explicitly stated 'substantial doubt' about the company's ability to continue as a going concern, which is a critical red flag for investors. While revenue increased, it was overshadowed by a disproportionate surge in general and administrative expenses, largely due to stock-based compensation, indicating poor cost control relative to revenue growth. The ineffectiveness of disclosure controls and ongoing legal disputes (Exotropin, former CSO) further compound the operational and governance risks. Despite some positive developments like the BioLumina acquisition and BioXtek JV, the fundamental financial instability and explicit going concern warning make this a high-risk investment with a strong likelihood of further value erosion. The reliance on dilutive capital raises in the future, coupled with a lack of clear path to profitability, suggests a strong sell recommendation.

Keywords

Biopharmaceutical, Regenerative Medicine, SEC Filing, 10-Q, Zofin, Patient Pure X, PPX, Aesthetic Biologics, FDA Regulations, Going Concern, Stock-based Compensation, Clinical Stage, Biologics License Application, HCT/Ps, BioXtek, Exotropin, Medical Devices, Healthcare Industry